Drugs Fut 2021, 46(2): 129

ISSN 0377-8282

Copyright 2021 Clarivate Analytics

CCC: 0377-8282

DOI: 10.1358/dof.2021.46.2.3176879

TNP-2092. RNA polymerase (bacterial) inhibitor, DNA gyrase (bacterial) inhibitor, DNA topoisomerase IV (bacterial) inhibitor, Treatment of medical device-associated bacterial biofilm infections

Takare, R., Dasgupta, A., Chopra, S.

The unrelenting rise of drug-resistant infections including those caused by biofilm-forming bacterial pathogens negatively impacts morbidity and mortality worldwide and demands the urgent discovery and development of novel therapeutics. In this context, TNP-2092 is a multitargeting drug conjugate that is designed to exert antibacterial activity by inhibiting 3 essential bacterial targets, such as RNA polymerase, DNA gyrase and topoisomerase IV, and consists of rifampicin and a quinolizinone-derived pharmacophore (ABT-719). The hybrid demonstrated more potent activity compared with both parent drugs individually and has a low propensity for resistance development since it targets 3 essential bacterial enzymes. The U.S. Food and Drug Administration (FDA) has granted fast track and orphan drug designations to TNP-2092 powder for intravenous injection for the treatment of prosthetic joint infections. TNP-2092 has also received a qualified infectious disease product designation in the U.S.

Link to the article: https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3176879&p_IsPs=N.‍

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com